Praxis Precision Medicines (NASDAQ:PRAX) Given Buy Rating at

Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at Truist Financial in a report released on Thursday, Benzinga reports. They currently have a $150.00 target price on the stock. Truist Financial’s target price suggests a potential upside of 233.70% from the stock’s current price. PRAX has been […]

Related Keywords

Robertw Baird , , Jump Financial , Citigroup Inc , Jefferies Financial Group , Praxis Precision Medicines Inc , Praxis Precision Medicines Company Profile , York Mellon Corp , Connor Clark Lunn Investment Management Ltd , Simplex Trading , Praxis Precision Medicines , Get Free Report , Truist Financial , Financial Group , Precision Medicines , Lunn Investment Management , New York Mellon Corp , Praxis Precision Medicines Daily ,